Audiologists in San Tan Valley, AZ Accepting Medicare
4 Audiologists found. Showing 1 - 4
 Elizabeth Lynn Diamond, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 36305 N Gantzel Rd Ste 104, San Tan Valley, AZ 85140 Phone: 480-331-6521 Fax: 480-420-3659 |
 Dr. Devin G Anderson, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 36305 N Gantzel Rd Ste 104, San Tan Valley, AZ 85140 Phone: 480-331-6521 Fax: 480-420-3659 |
Mrs. Kaitlyn Golemon, AU.D Audiologist Medicare: Medicare Enrolled Practice Location: 36305 N Gantzel Rd Ste 104, San Tan Valley, AZ 85140 Phone: 480-331-6521 Fax: 480-420-3659 |
 Priority Hearing And Tinnitus Audiologist Medicare: Medicare Enrolled Practice Location: 36305 N Gantzel Rd Ste 104, San Tan Valley, AZ 85140 Phone: 480-331-6521 Fax: 480-420-3659 |
News Archive
Medicare, health overhaul playing key role on the campaign trail
The Associated Press offers an issue breakdown regarding the health law positions taken by President Barack Obama and GOP presidential hopeful Mitt Romney while The Washington Post examines new studies that detail how Romney's Medicare proposals might impact seniors.
Cognitive neuroimaging offers answers to human engraved abstract motifs
Long before Lascaux paintings, humans engraved abstract motifs on stones, shells or egg shells. the earliest are 540,000 years old.
Emerging oral atypical antipsychotics to compete in increasingly crowded schizophrenia drug market
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the world's major pharmaceutical markets, emerging oral atypical antipsychotics will compete against each other and against established drugs for the same niche patient population in the treatment of schizophrenia.
ADVENTRX Pharmaceuticals submits a NDA for its vinorelbine injectable emulsion
ADVENTRX Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion).
Novel grape-derived compounds could be developed as therapeutic agents for treatment of depression
In a study to be published online February 2 in Nature Communications, scientists from the Icahn School of Medicine at Mount Sinai describe an extensive analysis of novel grape-derived compounds, dihydrocaffeic acid (DHCA) and malvidin-3'-O-glucoside (Mal-gluc),which might be developed as therapeutic agents for the treatment of depression.
› Verified 2 days ago
Physical Therapists
Occupational Therapists
Speech-Language Pathologists
Chiropractors
Optometrists
Audiologists